226 related articles for article (PubMed ID: 28726075)
1. Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents.
Ceylan MF; Erdogan B; Tural Hesapcioglu S; Cop E
Clin Drug Investig; 2017 Oct; 37(10):947-956. PubMed ID: 28726075
[TBL] [Abstract][Full Text] [Related]
2. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of long-acting injectable risperidone in a population of psychiatric out-patients: 1-year naturalistic study.
Di Lorenzo R; Fiorini F; Santachiara S
Psychopharmacol Bull; 2010; 43(1):39-52. PubMed ID: 20581799
[TBL] [Abstract][Full Text] [Related]
4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
5. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
Keith S
Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665
[TBL] [Abstract][Full Text] [Related]
6. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
8. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.
Keks NA; Ingham M; Khan A; Karcher K
Br J Psychiatry; 2007 Aug; 191():131-9. PubMed ID: 17666497
[TBL] [Abstract][Full Text] [Related]
9. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
10. Clinical review of a long-acting, injectable formulation of risperidone.
Knox ED; Stimmel GL
Clin Ther; 2004 Dec; 26(12):1994-2002. PubMed ID: 15823763
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.
Parellada E; Kouniakis F; Siurkute A; Schreiner A; Don L
Int Clin Psychopharmacol; 2010 May; 25(3):149-54. PubMed ID: 20305567
[TBL] [Abstract][Full Text] [Related]
12. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K
Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder.
Wu CS; Hsieh MH; Tang CH; Chang CJ
J Affect Disord; 2016 Jun; 197():189-95. PubMed ID: 26994437
[TBL] [Abstract][Full Text] [Related]
14. Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia.
Mohamed S; Rosenheck R; Harpaz-Rotem I; Leslie D; Sernyak MJ
Psychiatr Q; 2009 Dec; 80(4):241-9. PubMed ID: 19768543
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness, Good Tolerability, and High Compliance of Doses of Risperidone Long-Acting Injectable Higher Than 75 mg in People With Severe Schizophrenia: A 3-Year Follow-Up.
Fernández-Miranda JJ; Caramés-García V; Sánchez-García A
J Clin Psychopharmacol; 2015 Dec; 35(6):630-4. PubMed ID: 26421461
[TBL] [Abstract][Full Text] [Related]
16. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone.
Doknic M; Maric NP; Britvic D; Pekic S; Damjanovic A; Miljic D; Stojanovic M; Radojicic Z; Jasovic Gasic M; Popovic V
Neuroendocrinology; 2011; 94(3):246-54. PubMed ID: 21986470
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of prescription practices of long acting injectable risperidone in French hospitals].
Bret P; Heil M; Queuille E; Bret MC;
Encephale; 2011 May; 37 Suppl 1():S58-65. PubMed ID: 21600335
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder].
Benabarre A; Castro P; Sánchez-Moreno J; Martínez-Arán A; Salamero M; Murru A; Franco C; Vieta E
Actas Esp Psiquiatr; 2009; 37(3):143-7. PubMed ID: 19533426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
